1. Edwards, FC, Truelove, SC. The course and prognosis of ulcerative colitis. Part 1: short-term prognosis. Gut 1963; 4: 300–308.
Google Scholar | Crossref2. Dinesen, LC, Walsh, AJ, Protic, MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010; 4: 431–437.
Google Scholar | Crossref | Medline3. King, D, Rees, J, Mytton, J, et al. The outcomes of emergency admissions with ulcerative colitis between 2007 and 2017 in England. J Crohns Colitis 2020; 14: 764–772.
Google Scholar | Crossref | Medline4. Clemente, V, Aratari, A, Papi, C, et al. Short term colectomy rate and mortality for severe ulcerative colitis in the last 40 years. Has something changed? Dig Liver Dis 2016; 48: 371–375.
Google Scholar | Crossref | Medline5. Dong, C, Metzger, M, Holsbø, E, et al. Systematic review with meta-analysis: mortality in acute severe ulcerative colitis. Aliment Pharmacol Ther 2020; 51: 8–33.
Google Scholar | Crossref | Medline6. Turner, D, Walsh, CM, Steinhart, AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5: 103–110.
Google Scholar | Crossref | Medline | ISI7. Kaplan, GG, Seow, CH, Ghosh, S, et al . Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol 2012; 107: 1879–1887.
Google Scholar | Crossref | Medline | ISI8. Cohen, RD, Brodsky, AL, Hanauer, SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis 1999; 5: 1–10.
Google Scholar | Crossref | Medline9. Lichtiger, S, Present, DH, Kornbluth, A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 30: 1841–1845.
Google Scholar | Crossref10. Järnerot, G, Hertervig, E, Friis-Liby, I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805–1811.
Google Scholar | Crossref | Medline | ISI11. Laharie, D, Bourreille, A, Branche, J, et al.; Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909–1915.
Google Scholar | Crossref | Medline | ISI12. Williams, JG, Alam, MF, Alrubaiy, L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol 2016; 1: 15–24.
Google Scholar | Crossref | Medline13. Narula, N, Marshall, JK, Colombel, JF, et al. Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol 2016; 111: 477–491.
Google Scholar | Crossref | Medline | ISI14. Moskovitz, DN, Van Assche, G, Maenhout, B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4: 760–765.
Google Scholar | Crossref | Medline | ISI15. Laharie, D, Bourreille, A, Branche, J, et al. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 2018; 67: 237–243.
Google Scholar | Crossref | Medline16. Sjöberg, M, Magnuson, A, Björk, J, et al. Swedish Organization for the Study of Inflammatory Bowel Disease (SOIBD) . Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Aliment Pharmacol Ther 2013; 38: 377–387.
Google Scholar | Crossref | Medline17. Aratari, A, Papi, C, Clemente, V, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis 2008; 40: 821–826.
Google Scholar | Crossref | Medline18. Monterubbianesi, R, Aratari, A, Armuzzi, A, et al.; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. J Crohns Colitis 2014; 8: 852–858.
Google Scholar | Crossref | Medline19. Gustavsson, A, Järnerot, G, Hertervig, E, et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther 2010; 32: 984–989.
Google Scholar | Crossref | Medline20. Choy, MC, Seah, D, Faleck, DM, et al. Systematic review and meta-analysis: optimal salvage therapy in acute severe ulcerative colitis. Inflamm Bowel Dis 2019; 25: 1169–1186.
Google Scholar | Crossref | Medline21. Thorne, K, Alrubaiy, L, Akbari, A, et al. Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin: a systematic literature review. Eur J Gastroenterol Hepatol 2016; 28: 369–382.
Google Scholar | Crossref | Medline22. Magro, F, Gionchetti, P, Eliakim, R, et al.; European Crohn’s and Colitis Organisation (ECCO) . Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 2017; 11: 649–670.
Google Scholar | Crossref | Medline23. Truelove, SC, Witts, LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955; 2: 1041–1048.
Google Scholar | Crossref | Medline24. Chapman, RW, Selby, WS, Jewell, DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in acute severe ulcerative colitis. Gut 1986; 27: 1210–1212.
Google Scholar | Crossref | Medline25. Schroeder, KW, Tremaine, WJ, Ilstrup, DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Eng J Med 1987; 317: 1625–1629.
Google Scholar | Crossref | Medline | ISI26. Gionchetti, P, Rizzello, F, Annese, V, et al.; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. Dig Liver Dis 2017; 49: 604–617.
Google Scholar | Crossref | Medline27. Gustavsson, A, Halfvarson, J, Magnuson, A, et al. G. Long-term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era. Am J Gastroenterol 2007; 102: 2513–2519.
Google Scholar | Crossref | Medline28. Travis, SP, Farrant, JM, Ricketts, C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905–910.
Google Scholar | Crossref | Medline | ISI29. Carbonnel, F, Gargouri, D, Lémann, M, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000; 14: 273–279.
Google Scholar | Crossref | Medline30. Allison, J, Herrinton, LJ, Liu, L, et al. Natural history of severe ulcerative colitis in a community-based health plan. Clin Gastroenterol Hepatol 2008; 6: 999–1003.
Google Scholar | Crossref | Medline31. Lynch, RW, Lowe, D, Protheroe, A, et al. Outcomes of rescue therapy in acute severe ulcerative colitis: Data from the United Kingdom inflammatory bowel disease audit. Aliment Pharmacol Ther 2013; 38: 935–945.
Google Scholar | Crossref | Medline32. Llaó, J, Naves, JE, Ruiz-Cerulla, A, et al. Improved outcome of acute severe ulcerative colitis while using early predictors of corticosteroid failure and rescue therapies. Dig Liver Dis 2016; 48: 608–612.
Google Scholar | Crossref | Medline33. Reich, KM, Chang, HJ, Rezaie, A, et al. The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. Aliment Pharmacol Ther 2014; 40: 629–638.
Google Scholar | Crossref | Medline34. Ordás, I, Domènech, E, Mañosa, M, et al. Long-term efficacy and safety of cyclosporine in a cohort of steroid-refractory acute severe ulcerative colitis patients from the ENEIDA Registry (1989–2013): A nationwide multicenter study. Am J Gastroenterol 2017; 112: 1709–1718.
Google Scholar | Crossref | Medline35. Carbonnel, F, Lavergne, A, Lemann, M, et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994; 39: 1550–1557.
Google Scholar | Crossref | Medline | ISI36. Cacheux, W, Seksik, P, Lemann, M, et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008; 103: 637–642.
Google Scholar | Crossref | Medline37. Vedamurthy, A, Xu, L, Luther, J, et al. Long-term outcomes of immunosuppression-naïve steroid responders following hospitalization for ulcerative colitis. Dig Dis Sci 2018; 63: 2740–2746.
Google Scholar | Crossref | Medline